Eniluracil is under clinical development by Processa Pharmaceuticals and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I drugs for Pancreatic Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Eniluracil’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Eniluracil overview

Eniluracil is under development for the treatment of metastatic breast cancer, hepatocellular carcinoma and pancreatic cancer. The drug candidate is administered through oral route. It targets dihydropyrimidine dehydrogenase.

It was also under development for non-small cell lung carcinoma, gastric cancer, cervical cancer, prostate cancer and metastatic colorectal cancer.

Processa Pharmaceuticals overview

Processa Pharmaceuticals is a biopharmaceutical company that develops and commercializes drugs for the treatment of skin diseases and various cancer types. It is investigating its lead product candidate: PCS499 to treat necrobiosis lipoidica (NL), a chronic, disfiguring skin disorder and to treat the side effects of radiation in patients with head and neck cancer. The company’s PCS499 holds an Orphan Drug designation for the treatment of NL. It operates through its subsidiaries in Delaware, the US. Processa Pharmaceuticals is headquartered in Hanover, Maryland, the US.

For a complete picture of Eniluracil’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.